Jun 2026 (Q2 FY26) — Jul 30, 2026
Cerus Corporation Q2 FY26 — Strong Product Revenue Growth and Raised Guidance
Read the full callCerus (CERS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Cerus earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 57.4 | +9.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -3.2 | +3.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -2.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.22 +1.83% · +$0.04
Performance +45.1% 1Y
1Y: $1.53 on 17 Oct 2025 → $2.22. High $3.28 (6 Jul 2026), low $1.4 (30 Oct 2025).
- Previous close
- $2.18
- 52-week range
- $1.4 – $3.28
- One year
- +36.20%
Overview
- Symbol
- CERS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Cerus earnings calls (CERS)
Financials
What the filings say
Net profit, year on year: +48% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | — | 43 | 52 | — | — | 54 | 57 |
| Operating profit | -1 | -1 | -6 | -3 | 1 | -1 | -0 | -2 |
| Operating margin | — | — | −13.5% | −6.5% | — | — | −0.7% | −3.2% |
| Other income | -2 | -1 | -2 | -2 | -1 | -1 | -1 | -1 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -3 | -2 | -8 | -6 | 0 | -2 | -2 | -3 |
| Tax rate | −2.7% | −4.5% | −1.0% | −1.4% | 130.8% | −5.8% | −5.8% | −3.3% |
| Net profit | -3 | -3 | -8 | -6 | -0 | -2 | -2 | -3 |
| EPS ($ per share) | -0.02 | — | -0.04 | -0.03 | 0 | — | -0.01 | -0.01 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -779 | -850 | -910 | -964 | -1,007 | -1,045 | -1,066 | -1,081 |
| Total liabilities | 79 | 108 | 118 | 152 | 150 | 144 | 144 | 157 |
| Fixed assets | 8 | 15 | 14 | 12 | 11 | 9 | 7 | 9 |
| Total assets | 163 | 166 | 221 | 237 | 218 | 198 | 201 | 222 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -31 | -65 | -42 | -34 | -26 | -43 | 11 | 5 |
| Cash from investing | -44 | 28 | -50 | 13 | 8 | 9 | -8 | -6 |
| Cash from financing | 93 | 43 | 92 | 34 | 4 | 11 | 5 | 0 |
| Net cash flow | 18 | 6 | 1 | 12 | -14 | -24 | 8 | -1 |
| Capital expenditure | -1 | -9 | -2 | -1 | -2 | -5 | -3 | -4 |
| Free cash flow | -32 | -74 | -43 | -35 | -28 | -48 | 9 | 1 |
Insider filings
45 filings between Nov 24, 2025 and Aug 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$3.09M
22 sales by 6 insiders
95% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 23
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Greenman William Mariner | — | $1.20M | Jun 30, 2026 |
| Jayaraman Vivek K | — | $619.5K | Jul 16, 2026 |
| Green Kevin Dennis | — | $480.1K | Jun 30, 2026 |
| Benjamin Richard J | — | $419.5K | Mar 12, 2026 |
| Jensen Chrystal | — | $316.5K | Aug 17, 2026 |
| BJERKHOLT ERIC | — | $53.2K | Jun 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2026 | Jensen Chrystal Chief Legal Officer | Sale 10b5-1 plan | 30,000 | $89.5K |
| Jul 16, 2026 | Jayaraman Vivek K Chief Executive Officer | Sale 10b5-1 plan | 16,666 | $52.7K |
| Jul 1, 2026 | Jayaraman Vivek K Chief Operating Officer | Award 10b5-1 plan | 554,529 | $0 |
| Jun 30, 2026 | Greenman William Mariner President and CEO | Sale 10b5-1 plan | 101,919 | $299.9K |
| Jun 30, 2026 | Green Kevin Dennis Chief Financial Officer | Award 10b5-1 plan | 63,600 | $0 |
| Jun 30, 2026 | Green Kevin Dennis Chief Financial Officer | Sale 10b5-1 plan | 33,676 | $99.1K |
| Jun 30, 2026 | Jensen Chrystal Chief Legal Officer | Award 10b5-1 plan | 55,000 | $0 |
| Jun 30, 2026 | Jensen Chrystal Chief Legal Officer | Sale 10b5-1 plan | 24,329 | $71.6K |
| Jun 30, 2026 | Jayaraman Vivek K Chief Operating Officer | Award 10b5-1 plan | 80,000 | $0 |
| Jun 30, 2026 | Jayaraman Vivek K Chief Operating Officer | Sale 10b5-1 plan | 42,359 | $124.7K |
| Jun 30, 2026 | Greenman William Mariner President and CEO | Award 10b5-1 plan | 192,500 | $0 |
| Jun 9, 2026 | BJERKHOLT ERIC Director | Sale | 20,454 | $53.2K |
| Jun 2, 2026 | Shan Hua Director | Award | 60,000 | $0 |
| Jun 2, 2026 | Gregory Dean A. Director | Award | 60,000 | $0 |
| Jun 2, 2026 | Witney Frank Director | Award | 60,000 | $0 |
| Jun 2, 2026 | NACHTSHEIM JAMI K Director | Award | 60,000 | $0 |
| Jun 2, 2026 | BJERKHOLT ERIC Director | Award | 60,000 | $0 |
| Jun 2, 2026 | Lucena Ann Director | Award | 60,000 | $0 |
| May 29, 2026 | Jayaraman Vivek K Chief Operating Officer | Sale 10b5-1 plan | 16,667 | $50.0K |
| May 1, 2026 | Jayaraman Vivek K Chief Operating Officer | Sale 10b5-1 plan | 16,667 | $50.0K |
| Apr 1, 2026 | Jensen Chrystal Chief Legal Officer | Award 10b5-1 plan | 200,000 | $0 |
| Apr 1, 2026 | Green Kevin Dennis Chief Financial Officer | Award 10b5-1 plan | 200,000 | $0 |
| Mar 12, 2026 | Greenman William Mariner President and CEO | Sale 10b5-1 plan | 447,757 | $742.0K |
| Mar 12, 2026 | Benjamin Richard J Chief Medical Officer | Sale 10b5-1 plan | 101,740 | $168.6K |
| Mar 12, 2026 | Green Kevin Dennis Chief Financial Officer | Sale 10b5-1 plan | 127,544 | $211.4K |
| Mar 12, 2026 | Jayaraman Vivek K Chief Operating Officer | Sale 10b5-1 plan | 165,200 | $273.8K |
| Mar 9, 2026 | Benjamin Richard J Chief Medical Officer | Sale 10b5-1 plan | 40,426 | $76.0K |
| Mar 6, 2026 | Benjamin Richard J Chief Medical Officer | Sale 10b5-1 plan | 24,235 | $48.6K |
| Mar 6, 2026 | Jayaraman Vivek K Chief Operating Officer | Sale 10b5-1 plan | 34,094 | $68.4K |
| Mar 6, 2026 | Greenman William Mariner President and CEO | Sale 10b5-1 plan | 78,187 | $156.8K |
| Mar 6, 2026 | Green Kevin Dennis Chief Financial Officer | Sale 10b5-1 plan | 27,796 | $55.7K |
| Mar 6, 2026 | Jensen Chrystal Chief Legal Officer | Sale 10b5-1 plan | 30,845 | $61.9K |
| Mar 5, 2026 | Benjamin Richard J Chief Medical Officer | Award 10b5-1 plan | 55,220 | $0 |
| Mar 5, 2026 | Benjamin Richard J Chief Medical Officer | Sale 10b5-1 plan | 61,233 | $126.3K |
| Mar 5, 2026 | Green Kevin Dennis Chief Financial Officer | Sale 10b5-1 plan | 55,225 | $113.9K |
| Mar 5, 2026 | Jensen Chrystal Chief Legal Officer | Award 10b5-1 plan | 55,220 | $0 |
| Mar 5, 2026 | Greenman William Mariner President and CEO | Award 10b5-1 plan | 193,270 | $0 |
| Mar 5, 2026 | Jayaraman Vivek K Chief Operating Officer | Award 10b5-1 plan | 80,320 | $0 |
| Mar 5, 2026 | Green Kevin Dennis Chief Financial Officer | Award 10b5-1 plan | 63,854 | $0 |
| Mar 2, 2026 | Jensen Chrystal Chief Legal Officer | Award 10b5-1 plan | 300,000 | $0 |
| Mar 2, 2026 | Benjamin Richard J Chief Medical Officer | Award 10b5-1 plan | 264,000 | $0 |
| Mar 2, 2026 | Greenman William Mariner President and CEO | Award 10b5-1 plan | 1,200,000 | $0 |
| Mar 2, 2026 | Green Kevin Dennis Chief Financial Officer | Award 10b5-1 plan | 300,000 | $0 |
| Mar 2, 2026 | Jayaraman Vivek K Chief Operating Officer | Award 10b5-1 plan | 420,000 | $0 |
| Nov 24, 2025 | Jensen Chrystal Chief Legal Officer | Sale 10b5-1 plan | 55,000 | $93.5K |
| Aug 25, 2025 | Gregory Dean A. Director | Purchase | 25,000 | $31.3K |
| Jun 3, 2025 | Shan Hua Director | Award | 60,000 | $0 |
| Jun 3, 2025 | BJERKHOLT ERIC Director | Award | 60,000 | $0 |
| Jun 3, 2025 | Lucena Ann Director | Award | 60,000 | $0 |
| Jun 3, 2025 | NACHTSHEIM JAMI K Director | Award | 60,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CERUS CORP
Free account. Everything above stays public.
Write why you follow CERUS CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading